Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma

A model for anticancer drug development

M. E. Horowitz, E. Etcubanas, Michael Christensen, J. A. Houghton, S. L. George, A. A. Green, P. J. Houghton

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

We describe events that led to successful testing of melphalan, one of the nitrogen mustard compounds, in children with newly diagnosed, poor-risk rhabdomyosarcoma (RMS). Preclincal studies with xenografts of human RMS, growing in the flanks of immune-deprived mice, had indicated superior oncolytic activity by melphalan compared with other agents commonly used to treat this tumor. However, in a conventional phase II trial, melphalan failed to produce partial responses in 12 of 13 heavily pretreated patients with recurrent tumors. Subsequent comparison of the drug's pharmacokinetics in mice and patients indicated that its poor clinical performance was not the result of interspecies differences in drug disposition. Therefore, we elected to retest melphalan in untreated patients, before they were enrolled in a phase III study. Of 13 children who received the drug for 6 weeks, ten had partial responses, confirming the significant antitumor activity seen in the xenograft system. These findings illustrate the inherent limitations of phase II drug trials in previously treated patients and suggest a useful paradigm for the development of antineoplastic drugs.

Original languageEnglish (US)
Pages (from-to)308-314
Number of pages7
JournalJournal of Clinical Oncology
Volume6
Issue number2
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Melphalan
Rhabdomyosarcoma
Heterografts
Nitrogen Mustard Compounds
Pharmaceutical Preparations
Antineoplastic Agents
Neoplasms
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma : A model for anticancer drug development. / Horowitz, M. E.; Etcubanas, E.; Christensen, Michael; Houghton, J. A.; George, S. L.; Green, A. A.; Houghton, P. J.

In: Journal of Clinical Oncology, Vol. 6, No. 2, 01.01.1988, p. 308-314.

Research output: Contribution to journalArticle

Horowitz, M. E. ; Etcubanas, E. ; Christensen, Michael ; Houghton, J. A. ; George, S. L. ; Green, A. A. ; Houghton, P. J. / Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma : A model for anticancer drug development. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 2. pp. 308-314.
@article{b67b61cbd96a495da078918190a416de,
title = "Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development",
abstract = "We describe events that led to successful testing of melphalan, one of the nitrogen mustard compounds, in children with newly diagnosed, poor-risk rhabdomyosarcoma (RMS). Preclincal studies with xenografts of human RMS, growing in the flanks of immune-deprived mice, had indicated superior oncolytic activity by melphalan compared with other agents commonly used to treat this tumor. However, in a conventional phase II trial, melphalan failed to produce partial responses in 12 of 13 heavily pretreated patients with recurrent tumors. Subsequent comparison of the drug's pharmacokinetics in mice and patients indicated that its poor clinical performance was not the result of interspecies differences in drug disposition. Therefore, we elected to retest melphalan in untreated patients, before they were enrolled in a phase III study. Of 13 children who received the drug for 6 weeks, ten had partial responses, confirming the significant antitumor activity seen in the xenograft system. These findings illustrate the inherent limitations of phase II drug trials in previously treated patients and suggest a useful paradigm for the development of antineoplastic drugs.",
author = "Horowitz, {M. E.} and E. Etcubanas and Michael Christensen and Houghton, {J. A.} and George, {S. L.} and Green, {A. A.} and Houghton, {P. J.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1200/JCO.1988.6.2.308",
language = "English (US)",
volume = "6",
pages = "308--314",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma

T2 - A model for anticancer drug development

AU - Horowitz, M. E.

AU - Etcubanas, E.

AU - Christensen, Michael

AU - Houghton, J. A.

AU - George, S. L.

AU - Green, A. A.

AU - Houghton, P. J.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We describe events that led to successful testing of melphalan, one of the nitrogen mustard compounds, in children with newly diagnosed, poor-risk rhabdomyosarcoma (RMS). Preclincal studies with xenografts of human RMS, growing in the flanks of immune-deprived mice, had indicated superior oncolytic activity by melphalan compared with other agents commonly used to treat this tumor. However, in a conventional phase II trial, melphalan failed to produce partial responses in 12 of 13 heavily pretreated patients with recurrent tumors. Subsequent comparison of the drug's pharmacokinetics in mice and patients indicated that its poor clinical performance was not the result of interspecies differences in drug disposition. Therefore, we elected to retest melphalan in untreated patients, before they were enrolled in a phase III study. Of 13 children who received the drug for 6 weeks, ten had partial responses, confirming the significant antitumor activity seen in the xenograft system. These findings illustrate the inherent limitations of phase II drug trials in previously treated patients and suggest a useful paradigm for the development of antineoplastic drugs.

AB - We describe events that led to successful testing of melphalan, one of the nitrogen mustard compounds, in children with newly diagnosed, poor-risk rhabdomyosarcoma (RMS). Preclincal studies with xenografts of human RMS, growing in the flanks of immune-deprived mice, had indicated superior oncolytic activity by melphalan compared with other agents commonly used to treat this tumor. However, in a conventional phase II trial, melphalan failed to produce partial responses in 12 of 13 heavily pretreated patients with recurrent tumors. Subsequent comparison of the drug's pharmacokinetics in mice and patients indicated that its poor clinical performance was not the result of interspecies differences in drug disposition. Therefore, we elected to retest melphalan in untreated patients, before they were enrolled in a phase III study. Of 13 children who received the drug for 6 weeks, ten had partial responses, confirming the significant antitumor activity seen in the xenograft system. These findings illustrate the inherent limitations of phase II drug trials in previously treated patients and suggest a useful paradigm for the development of antineoplastic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0023832837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023832837&partnerID=8YFLogxK

U2 - 10.1200/JCO.1988.6.2.308

DO - 10.1200/JCO.1988.6.2.308

M3 - Article

VL - 6

SP - 308

EP - 314

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -